Company Overview
Genenta Science S.p.A. operates as a clinical-stage biotechnology company focused on the development of hematopoietic stem cell gene therapies designed to treat solid tumors within the Italian market. The company's primary therapeutic target is glioblastoma, with its lead product candidate, Temferon, currently progressing through Phase 1/2a clinical trials. This entity functions within the broader Healthcare sector and the specific Biotechnology industry, where it leverages advanced cellular engineering to address critical unmet medical needs in oncology. In terms of scale, the company holds a market capitalization of $16.63M and employs 13 individuals, reflecting a small-cap status typical of early-stage biotechnology firms. The combination of a market cap under $20M and the absence of reported annual revenue indicates that Genenta Science is in a pre-commercialization phase, where value is derived entirely from intellectual property and clinical progress rather than current sales or cash flow generation.
Financial Health
The company reports no revenue for the trailing twelve months, resulting in a net income of $-8,700,574 and an EBITDA of $-8,592,703, which highlights a cost structure dominated by research and development expenses rather than operational overhead. Free cash flow stands at $-6,383,307, signifying that the company is burning cash to fund its clinical trials and operational needs, thereby limiting its immediate financial flexibility without external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard characteristic for pre-revenue biotechnology companies that have not yet generated sales to calculate profitability. On the balance sheet, the company holds $17.67M in cash against $7.55M in debt, creating a net cash position that provides a buffer against its ongoing burn rate. The debt-to-equity ratio is 62.37, suggesting a leveraged capital structure relative to equity, yet the high current ratio of 13.20 indicates robust short-term liquidity and an ability to meet obligations with current assets. Return on Equity is -60.1% and Return on Assets is -26.6%, metrics that reveal management is utilizing shareholder capital to fund high-risk growth initiatives rather than generating immediate returns. These negative return figures are consistent with the company's stage of development, where capital is being deployed to de-risk clinical candidates before commercialization can occur.
Valuation Assessment
The company presents a trailing P/E ratio of N/A due to its lack of net income, while the forward P/E is listed as -1.09, implying that analysts are pricing in future earnings potential based on projected clinical successes rather than historical profitability. The price-to-book ratio is 0.97, indicating that the market values the company at approximately equal to its book value, which often occurs with pre-commercial entities where tangible assets are minimal compared to intangible R&D assets. Alternative valuation metrics such as price-to-sales (N/A) and EV/EBITDA (-0.40) further underscore the speculative nature of the investment, as these ratios rely on earnings or sales data that do not yet exist for this clinical-stage asset. The stock has traded between a 52-week low of $0.59 and a 52-week high of $10.00, a range that illustrates the extreme volatility often associated with biotechnology stocks dependent on singular clinical trial outcomes. With a beta of 0.56, the stock exhibits lower price volatility relative to the broader market, suggesting that its price movements are less sensitive to general market swings and more correlated with specific sector or company news.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not generated positive revenue to calculate meaningful growth rates over a trailing period. Consequently, the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings and cash reserves are reinvested directly into research, development, and clinical operations. The absence of a payout ratio confirms that the company prioritizes funding its Phase 1/2a trials for Temferon over returning capital to shareholders, a common strategy for clinical-stage biotechs seeking to extend their cash runway. This financial profile characterizes Genenta Science as a pure growth play with no current income generation, where value accrual is entirely contingent on the successful advancement of its lead asset through clinical milestones.